HCV genotype 5: An orphan virus

Antiviral Therapy

Volumn 18, Issue 3, 2013, Pages 263-269

  Antaki, Nabil ^a   Abboud, Dirar ^a   Antaki, Fadi ^b   Craxi, Antonio ^c  

^a Saint Louis Hospital   (Syrian Arab Republic)

^b WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF PALERMO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BOCEPREVIR; HOST FACTOR; PEGINTERFERON ALPHA2A PLUS RIBAVIRIN; PEGINTERFERON ALPHA2B PLUS RIBAVIRIN; SIMEPREVIR; TELAPREVIR;

BLOOD TRANSFUSION; DRUG EFFICACY; DRUG POTENCY; GENETIC HETEROGENEITY; GEOGRAPHIC DISTRIBUTION; HEPATITIS C; HEPATITIS C VIRUS; HEPATITIS C VIRUS GENOTYPE 5; HUMAN; IATROGENIC DISEASE; INCIDENCE; PATIENT CARE; PHYLOGENY; PREVALENCE; PRIORITY JOURNAL; REVIEW; SEQUENCE ALIGNMENT; VIRUS LOAD; VIRUS STRAIN; VIRUS TRANSMISSION;

ANTIVIRAL AGENTS; GENOTYPE; HEPACIVIRUS; HEPATITIS C; HOST-PATHOGEN INTERACTIONS; HUMANS; PREVALENCE; TREATMENT OUTCOME;

EID: 84878033514     PISSN: 13596535     EISSN: 20402058     Source Type: Journal    
DOI: 10.3851/IMP2449     Document Type: Review

References (45)

1. European Association for the study of the Liver. EASL Clinical Practice Guidelines: Management of hepatitis C virus infection. J Hepatol 2011; 55:245-264.
2. Lavanchy D. Evolving epidemiology of hepatitis C virus. Clin Microbiol Infect 2011; 17:107-115.
3. Simmonds P, Bukh J, Combet C, et al. Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes. Hepatology 2005; 42:962-973.
4. Antaki N, Craxi A, Kamal S, et al. The neglected hepatitis C virus genotypes 4, 5 and 6: an international consensus report. Liver Int 2010; 30:342-355.
5. Prabdial-Sing N, Puren AJ, Mahlangu J, Barrow P, Bowyer SM. Hepatitis C virus genotypes in two different patient cohorts in Johannesburg, South Africa. Arch Virol 2008; 153:2049-2058.
6. Verbeeck J, Maes P, Lemey P, et al. Investigating the origin and spread of hepatitis C virus genotype 5a. J Virol 2006; 80:4220-4226.
7. Henquell C, Cartau C, Abergel A, et al. High prevalence of hepatitis C virus type 5 in Central France evidenced by a prospective study from 1996 to 2002. J Clin Microbiol 2004; 42:3030-3035.
8. Jover R, Perez-Serra J, de Vera F, et al. Infection by genotype 5a of HCV in a district of southeast Spain. Am J Gastroenterol 2001; 96:3042-3043.
9. Antaki N, Haddad M, Kebbewar K, et al. The unexpected discovery of a focus of hepatitis C virus genotype 5 in a Syrian province. Epidemiol Infect 2009; 137:79-84.
10. Bernier L, Willems B, Delage G, Murphy DG. Identification of numerous hepatitis C virus genotypes in Montreal, Canada. J Clin Microbiol 1996; 34:2815-2818.
11. Levi JE, Takaoka DT, Garrini RH, et al. Three cases of infection with hepatitis C virus genotype 5 among Brazilian hepatitis patients. J Clin Microbiol 2002; 40:2645-2647.
12. Shobokshi OA, Serebour FE, Skakni LI. Hepatitis C genotypes/subtypes among chronic hepatitis patients in Saudi Arabia. Saudi Med J 2003; 24 Suppl 2:S87-91.
13. Karatapanis S, Tsoplou P, Papastergiou V, et al. Hepatitis C virus genotyping in Greece: unexpected high prevalence of genotype 5a in a Greek island. J Med Virol 2012; 84: 223-228.
14. Pybus OG, Charleston MA, Gupta S, Rambaut A, Holmes EC, Harvey PH. The epidemic behavior of the hepatitis C virus. Science 2001; 292:2323-2325.
15. Ndjomou J, Pybus OG, Matz B. Phylogenetic analysis of hepatitis C virus isolates indicates a unique pattern of endemic infection in Cameroon. J Gen Virol 2003; 84:2333-2341.
16. Pouillot R, Lachenal G, Pybus OG, Rousset D, Njouom R. Variable epidemic histories of hepatitis C virus genotype 2 infection in West Africa and Cameroon. Infect Genet Evol 2008; 8:676-681.
17. Henquell C, Guglielmini J, Verbeeck J, Mahul A, Thibault V, Lebray P et al. Evolutionary history of hepatitis C virus genotype 5a in France, a multicenter ANRS study. Infect Genet Evol 2011; 11:496-503.
18. Verbeeck J, Kwanten L, D'Heygere F, et al. HCV genotype distribution in Flanders and Brussels (Belgium): unravelling the spread of an uncommon HCV genotype 5a cluster. Eur J Clin Microbiol Infect Dis 2010; 29:1427-1434.
19. Abergel A, Ughetto S, Dubost S, et al. The epidemiology and virology of hepatitis C virus genotype 5 in central France. Aliment Pharmacol Ther 2007; 26:1437-1446.
20. Nieuwoudt M, Arazi A, Neumann A, Van der Merwe SW. Viral kinetics of HCV genotype 5 in South Africa patients treated with pegylated-interferon-alpha and ribavirin. Hepatology 2007; 46:367A.
21. Legrand-Abravanel F, Sandres-Sauné K, Barange K, et al. Hepatitis C virus genotype 5: epidemiological characteristics and sensitivity to combination therapy with interferon-alpha plus ribavirin. J Infect Dis 2004; 189:1397-1400.
22. D'Heygere F, George C, Nevens F. Patients infected with HCV-5 present the same response rate as patients infected with HCV-1: results from the Belgian randomized trial for naive and relapsers (BERNAR-1). J Hepatol 2005; 42:203A.
23. Antaki N, Hermes A, Hadad M, et al. Efficacy of interferon plus ribavirin in the treatment of hepatitis C virus genotype 5. J Viral Hepat 2008; 15:383-386.
24. Bonny C, Fontaine H, Poynard T, et al. Effectiveness of interferon plus ribavirin combination in the treatment of naive patients with hepatitis C virus type 5. A French multicentre retrospective study. Aliment Pharmacol Ther 2006; 24:593-600.
25. D'Heygere F, George C, Van Vlierberghe H, et al. Efficacy of interferon-based antiviral therapy in patients with chronic hepatitis C infected with genotype 5: a meta-analysis of two large prospective clinical trials. J Med Virol 2011; 83: 815-819.
26. Antaki N, Bibert S, Kebbewar K, et al. IL28B polymorphisms do not predict response to therapy in chronic hepatitis C with HCV genotype 5. Gut 2012; 61:1640-1641.
27. Ge D, Fellay J, Thompson AJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009; 461:399-401.
28. Suppiah V, Moldovan M, Ahlenstiel G, et al. IL28B is associated with response to chronic hepatitis C interferon-α and ribavirin therapy. Nat Genet 2009; 41:1100-1104.
29. Tanaka Y, Nishida N, Sugiyama M, et al. Genome-wide association of IL28B with response to pegylated interferon-α and ribavirin therapy for chronic hepatitis C. Nat Genet 2009; 41:1105-1109.
30. De Nicola S, Aghemo A, Rumi MG, et al. An IL28B polymorphism predicts pegylated interferon plus ribavirin treatment outcome in chronic hepatitis C genotype 4. Hepatology 2012; 55:336-342.
31. Asselah T, De Muynck S, Broët P, et al. IL28B polymorphism is associated with treatment response in patients with genotype 4 chronic hepatitis C. J Hepatol 2012; 56:527-532.
32. Antaki N, Bibert S, Kebbewar K, Asaad F, Baroudi O, Alideeb S et al. IL28B polymorphisms predict response to therapy in chronic hepatitis C with HCV genotype 4. J Viral Hepat 2013; 20: 59-64.
33. Rauch A, Kutalik Z, Descombes P, et al. Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study. Gastroenterology 2010; 138:1338-1345.
34. Mangia A, Thompson AJ, Santoro R, et al. IL28B polymorphism determines treatment response of patients with hepatitis C genotypes 2 or 3 who do not achieve a rapid virologic response. Gastroenterology 2010; 139:821-827.
35. Hinrichsen H, Benhamou Y, Wedemeyer H, et al. Short-term antiviral efficacy of BILN 2061, a hepatitis C virus serine protease inhibitor, in hepatitis C genotype 1 patients. Gastroenterology 2004; 127:1347-1355.
36. Reiser M, Hinrichsen H, Benhamou Y, et al. Antiviral efficacy of NS3-serine protease inhibitor BILN-2061 in patients with chronic genotype 2 and 3 hepatitis C. Hepatology 2005; 41:832-835.
37. Reesink HW, Zeuzem S, Weegink CJ, et al. Rapid decline of viral RNA in hepatitis C patients treated with VX-950: a Phase Ib, placebo-controlled, randomized study. Gastroenterology 2006; 131:997-1002.
38. Foster GR, Hézode C, Bronowicki JP, et al. Telaprevir alone or with peginterferon and ribavirin reduces HCV RNA in patients with chronic genotype 2 but not genotype 3 infections. Gastroenterology 2011; 141:881-889.
39. Benhamou Y, Moussalli J, Ratziu V, et al. Results of a proof of concept study (C210) of telaprevir monotherapy and in combination with peginterferon alfa-2a and ribavirin in treatment-naïve genotype 4 HCV patients. J Hepatol 2009; 50: S6.
40. Silva M, Treitel M, Graham DJ, et al. Antiviral activity of Boceprevir monotherapy in treatment-naive subjects with chronic hepatitis C genotype 2/3. Hepatol Int 2013; doi: 10.1016/j.jhep.2013.02.018.
41. Moreno C, Berg T, Tanwandee T, et al. Antiviral activity of TMC435 monotherapy in patients infected with HCV genotypes 2-6: TMC435-C202, a Phase IIa, open-label study. J Hepatol 2012; 56: 1247-1253.
42. Gottwein JM, Scheel TK, Jensen TB, Ghanem L, Bukh J. Differential efficacy of protease inhibitors against HCV genotypes 2a, 3a, 5a, and 6a NS3/4A protease recombinant viruses. Gastroenterology 2011; 141:1067-1079.
43. Scheel TK, Gottwein JM, Mikkelsen LS, Jensen TB, Bukh J. Recombinant HCV variants with NS5A from genotypes 1-7 have different sensitivities to an NS5A inhibitor but not interferon-α. Gastroenterology 2011; 140:1032-1042.
44. Gao M, Nettles RE, Belema M, et al. Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect. Nature 2010; 465:96-100.
45. Hassanein T, Nelson DR, Lawitz E, et al. PSI-7977 with PEG/RBV elicits rapid declines in HCV RNA in patients with HCV GT-4 and GT-6. Global Antiviral Journal 2011;7 Suppl 1:57-58.